Home
NewsNewsNexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
Nexpring Health, a global leader in assisted reproductive technology (ART) solutions, has announced a strategic investment in May Health, a medical device company. This partnership aims to advance a pioneering treatment for PCOS-Related Infertility, addressing a significant gap in women's health. Nexpring Health joined a €10 million ($11.7M) financing round alongside other key investors, including Sofinnova Partners, Trill Impact, and Bpifrance.
Polycystic ovary syndrome (PCOS) is a widespread endocrine condition affecting approximately 10–13% of reproductive-aged women worldwide. It stands as a primary cause of female infertility, as the condition often prevents consistent ovulation. For many patients, the struggle to conceive is a defining challenge, leading to a critical need for innovative solutions to manage PCOS-Related Infertility.
May Health’s breakthrough technology, the Anavi™ System, offers a novel approach to this issue. It is designed as a one-time, office-based procedure intended to restore ovulation in women who have not responded to or are unable to use traditional first-line therapies. The system has already reached significant milestones, receiving CE Mark certification in October 2025. Currently, May Health is advancing its pivotal U.S. Investigational Device Exemption (IDE) trial, known as the REBALANCE study, as it seeks FDA marketing authorisation. The REBALANCE trial is a multicentre, randomised controlled study currently enrolling participants at over 15 fertility centres across the United States.
Wil Boren, CEO of Nexpring Health, emphasised that the investment reflects the company’s commitment to redefining fertility care and supporting innovations that change patient outcomes. Boren stated that May Health’s work helps move the entire field forward by expanding clinical options for both professionals and patients. Colby Holtshouse, President and CEO of May Health, added that women have long required more options to support their family-building journeys while managing PCOS-Related Infertility.
Through this collaboration, Nexpring Health continues its mission of placing clinicians and embryologists at the centre of every breakthrough. By backing the Anavi™ System, the company aims to provide reproductive medicine professionals with the tools needed to deliver consistent, confident outcomes for those hoping to start a family
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
INVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
Costco, Sesame, and IVI RMA North America have announced strategic partnership to alter fertility care in the U.S. by removing biggest obstacles to care including high costs and limited access.
Carea has launched its Trying to Conceive - IVF/IUI mode to help women undergoing intricate fertility treatment with risks of inconsistent clinic continuity through continuous tracking and expert guidance.
The Minnesota bill for infertility treatments mandates comprehensive insurance coverage for diagnosis, IVF, and fertility preservation across public and private health plans. Set for implementation in 2027, the legislation expands access, modernises infertility definitions, and ensures cost-sharing protections to make reproductive healthcare more equitable.
